相似文献
1
[Herceptin monotherapy in HER2(+) recurrent breast carcinoma].
Onkologie. 2002 Dec;25 Suppl 5:14-5.
2
[DCIS and HER2/neu].
Onkologie. 2002 Dec;25 Suppl 5:11-2; discussion 13.
3
[Combination therapy herceptin+taxotere/Herceptin+navelbine].
Onkologie. 2002 Dec;25 Suppl 5:15-6.
4
Dual HER2 Blockade Helps Prevent Breast Cancer Return.
Cancer Discov. 2017 Aug;7(8):790. doi: 10.1158/2159-8290.CD-NB2017-086. Epub 2017 Jun 6.
5
Trastuzumab (herceptin) for early-stage breast cancer.
Hematol Oncol Clin North Am. 2007 Apr;21(2):239-56. doi: 10.1016/j.hoc.2007.03.003.
6
Current perspective - trastuzumab.
Eur J Cancer. 2009 Jan;45(1):12-8. doi: 10.1016/j.ejca.2008.10.013. Epub 2008 Nov 29.
7
Clinicopathologic characteristics of HER2 FISH-ambiguous breast cancer at a single institution.
Am J Surg Pathol. 2013 Jan;37(1):120-7. doi: 10.1097/PAS.0b013e31826ab19d.
8
[Breast cancer: adjuvant therapy with trastuzumab: herceptin adjuvant (HERA) Trial Study, B-31- and N9831-Study].
Internist (Berl). 2006 Nov;47(11):1183-5. doi: 10.1007/s00108-006-1720-x.
9
[Herceptin, a monoclonal humanized antibody anti-HER2: a major therapeutic progress in breast cancers overexpressing this oncogene?].
Bull Cancer. 1999 Jun;86(6):544-9.
10
Cardiac toxicity monitoring for HER2-positive breast cancer patients undergoing trastuzumab therapy: are we doing enough?
Clin Oncol (R Coll Radiol). 2013 Jul;25(7):446-7. doi: 10.1016/j.clon.2013.03.006. Epub 2013 Apr 11.
Zotero 插件